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The SARS-CoV-2 disease (COVID-19) outbreak, officially categorized as a pandemic in 
March 2020, poses a greater risk for individuals with pre-disposed chronic conditions. It is 
important to analyze the clinical characteristics of COVID-19 and identify risk factors to reduce 
the incidence of severe symptoms. Individuals have chronic conditions are at a higher risk of rapid 
disease progression. However, personal characteristics such as age, gender, and ethnicity can be 
vital factors regarding disease severity. The aim of this study is to analyze the discrepancies of 
patients with different comorbidities and risk factors for severe COVID-19 by comparing the 
epidemiological and clinical data of 50 patients from UPMC Mercy in Pittsburgh, Pa. A systematic 
review was conducted to collect and evaluate the associations of epidemiological and comorbidity 
factors with the severity and prognosis of COVID-19. This study will dive into 16 comorbidities 
and compartmentalize them by similar characteristics to further exam divergences. The age, 
gender, length of stay, ventilation, mortality, and other variants were utilized during this study. 
The average age for severe disease progression is 78 years old. Males were more susceptible to 
severe cases of COVID-19. Nearly 80% of patients had Hypertension (HTN). The diagnosis of 
hypertension was present in 93% of severe cases. Ventilation treatment was observed in 46% of 
patients and 30% of patients were placed in the ICU. The Comorbidity with the highest index is 
Cancer (9), the most prevalent comorbidity is hypertension (Frequency 64%). Our findings suggest 
 v 
a correlation in severity between age and comorbidity as well as severity and zip code. Additional 
research is needed to further understand the severity of COVID-19’s progression.  
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Charlson Comorbidity Index: a method that is used to categorize comorbidities of patients based 
on the International Classification of Diseases (ICD) diagnosis codes found in administrative data.  
Chronic Disease: conditions that last more than one year and requires on-going medical attention; 
limits activities of daily living 
Comorbidity: The simultaneous presence of two or more diseases or medical conditions in a 
patient. 
Epidemiology: The branch of medicine which deals with the incidence, distribution and possible 
control of disease and other factors relating to health. 
Risk Factor: In epidemiology, it is a variable associated with an increased risk of diseases or 
infection. 
R Naught (R0): the average number of cases of an infectious disease arising by transmission from 
a single infected individual in an area that has not been exposed. 
Sars-Cov-2: a member of a large family of viruses called coronavirus.  
Surveillance: The continued watchfulness over the distribution and trends of incidence through 





This is made in conjunction with UPMC Mercy Infectious Disease Department and the 
University of Pittsburgh Graduate School or Public Health. 
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1.0 Introduction 
1.1 What is the coronavirus? 
The coronavirus is a type of virus composed of the phylogenetically distinct taxonomic 
subgroups alpha and beta (𝛼 𝑎𝑛𝑑 𝛽). The World Health Organization defines the coronavirus as a 
large family of viruses that causes illness that resembles the common cold or severe acute 
respiratory disease. The strain nCoV is a new strain that has recently crossed over to humans 1.  
SARS-CoV, MERS-CoV, and SARS-CoV-2 are related to the 𝛽-Coronavirus cluster. Both SARS 
viruses are from enzootic in Rhinolophus or horseshoe bats. The figure below depicts the main 
subtypes of the coronavirus and the strains within each category. 
1.2 Life Cycle of COVID-19 
The virus is inhaled and enters cells in the lungs that express the ACE-2 receptor, a 
chimeric protein wherein SARS-CoV and SARS-CoV-2 bind ACE2 2. ACE2 is differentiated from 
other viral receptors in that it interfaces with a major endocrine vasoactive signaling pathway, the 
renin-angiotensin-aldosterone system (RAAS)2. ACE2 is present in the GI tract, adipose tissue, 
arterial and venous endothelial cells, heart, kidney, liver, and mucosa of the oral cavity 2, which is 
why underlying conditions such as heart failure and diabetes are observed. ACE2 levels change in 
                                                 
1 WHO, 2020 
2 Richard, 2020 
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obesity, diabetes, heart disease, hypertension, and kidney and lung disease, which is another 
differentiating characteristic of this viral receptor 2; therefore, by increasing viral internalization, 
ACE2 upregulation may enhance the viral load and increase disease severity 2. After penetration, 
the cell engulfs the virus, and it releases its RNA. This prompts cellular replication wherein the 
RNA particles are assembled and packages, as shown in the figure above. RNA replications occur, 
the virus spreads, and the immune response begins. 
1.3 Epidemiology of COVID-19 
Data supports the theory, “emergence over detection.” Disease emergence requires a bridge 
from the natural host to a susceptible spillover host with the ability to adapt as time progress 3. 
This notion stems from the long-term circulation of these viruses remaining in their host until 
something prompts their spillover.  
Scientists have uncovered numerous animal reservoirs of Coronavirus, mainly in Africa, 
Asia, and America. Over the past decade, the coronaviral ecosystem, viral response, and risk of 
spillover from animal to human have become more well understood. For example, the SARS-CoV 
virus originates from wet markets in the southern area of Asia, with the Rhinolophus species being 
the natural host. Research shows that the cages from these wet markets are often crowded and 
heavily contaminated with feces, expired food, and poorly maintained living conditions. Targeted 
surveillance and improved diagnostics are not efficient enough to explain the emergence of these 
viruses 3. Disease outbreak evidence supports the notion that the coronavirus outbreaks were 
                                                 
3 Field, 2009 
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inevitable as crossover events between humans and the animal reservoirs are becoming impossible 
to avoid. Thus, various coronavirus strains have emerged recently (SARS-COV and SAR-COv-2) 
as scientists believe that this is only the beginning.  
The SARS-CoV-2 disease (COVID-19) outbreak, officially categorized as a pandemic in 
March 2020, poses a greater risk for individuals with pre-disposing chronic conditions. It is slightly 
different from other strains of the coronavirus due to its high transmission rate. The course of 
COVID-19 illness can progress rapidly, causing acute respiratory distress syndrome, 
Gastroesophageal reflux (GERD), and pneumonia. Patients with the disease present with fever, 
cough, and shortness of breath within 2 to 14 days after exposure.  It is essential to analyze the 
clinical characteristics of COVID-19 and identify risk factors to reduce the incidence of severe 
symptoms. Individuals who have chronic conditions are at a higher risk of rapid disease 
progression. However, personal characteristics such as age, gender, and ethnicity can be vital 
factors regarding disease severity. It is imperative to understand the virus, its interaction with the 




The aim of this study is to analyze the discrepancies of patients with different comorbidities 
and risk factors for severe COVID-19 by comparing the epidemiological and clinical data of 50 
patients from UPMC Mercy in Pittsburgh, Pa. We hypothesize that the number of risk factors 
experienced by each pre-disposed patient will increase the speed of progression of the virus at a 
higher rate varying certain risk characteristics during hospitalization. We would also like to 
highlight additional personal characteristics, risk factors and comorbidities that increases disease 
severity for public knowledge. Severity was measured by combining causes such as patients on 
ventilation systems, admitted into the ICU, and death records. Non-severe cases included patients 
who did not need supplemental oxygen, were not admitted to the ICU, and released from the 
hospital after five days. 
2.1 UPMC Mercy 
UPMC Mercy hospital is a level I (highest level) Trauma center designed to treat severe or 
life-threatening illnesses. A retrospective review of 50 inpatients at UPMC Mercy Hospital 
Pittsburgh, PA, was conducted between October 2020 and March 2021 to collect and evaluate the 
associations of epidemiological comorbidity factors with the severity and prognosis of COVID-
19. 120 patients who tested positive for COVID19 were screened, and 50 of these patients were 
chosen randomly and thoroughly reviewed. Fifteen variables were recorded, including length of 
stay, Zip code, social history, blood pressure, and height. The screening process relied on patient 
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charts that were continuously updated during the study. Next, the data were entered into Microsoft 
Excel to calculate the statistical information necessary to accept the hypothesis.  
2.2 Prognosis  
This study utilized prognosis endpoints to predict COVID-19 outcomes. The prognosis in 
this study is the probability of risks of an individual developing COVID-19 throughout 12 months 
based on personal and clinical characteristics. This tool will aid in predicting disease progression 
4as a general stance. Prognosis can surround a patient’s gender, age, test results (positive COVID-
19), and symptoms4. A modified version of the Charlson Comorbidity Index will aid in 
determining the risk of a more severe case given the combination of causation of predictor values 
4. As these patients are in the UPMC Mercy’s database, there are endless possibilities for future 
studies such as vaccine reactions, hospital performance differentials amongst the UPMC 
organization, mortality rates, and possibly clinical studies as information is continuously updated. 
2.3 Chronic Disease 
During the beginning of the pandemic, there were many uncertainties about the effects of 
the COVID-19 per individual. Research shows that patients with underlining health conditions are 
more prominent amongst those with more severe prognosis. Those underlining health conditions 
included chronic diseases such as diabetes, hypertension, cardiovascular disease, obesity, and renal 
                                                 
4 Moons, 2009 
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diseases. The CDC’s definition of chronic diseases is defined broadly as “conditions that last one 
year or more and require ongoing medical attention or limit activities of daily living” 5.  
Diabetes is one of the leading causes of death. It is a chronic disease that occurs when the 
pancreas can no longer produce insulin effectively or often when the body has issues utilizing the 
produced dosage 6. Chronic conditions such as diabetes have been implicated as a risk factor for 
poor prognosis in hospitalized patients with COVID-19. Diabetes mellitus is a significant 
contributor to mortality from COVID‐19, with a rate of 7.3 to 35.5% globally 7. In this study, 40% 
of patients suffered from diabetes. The patients’ severity was increased with additional underlying 
medical issue that are outlined in this section. 
Hypertension, known to the public as high blood pressure, is another chronic disease that 
many individuals suffer. Scientifically, it is “when the force of your blood pushing against the 
walls of your blood vessels, is consistently high” 8. Hypertension can be an underlying condition 
to another chronic illness called cardiovascular disease. Many of the patients suffered from high 
blood pressure, aiding to disease severity. 
Cardiovascular disease, chronic heart failure, is when atherosclerosis affects the heart. 
Atherosclerosis is a condition that develops when plaque builds up in the walls of the arteries 8. 
Due to the commonality of this disease, many hospitalized COVID-19 patients endure this chronic 
disease as its effects are hypothesized to add to the severity of disease progression. A study in 
China evaluated the clinical characteristics of patients admitted for COVID‐19 infection and 
                                                 
5 CDC, 2021 
6 IDF,2020 
7 Anjorin, 2021 
8 AHA, 2016 
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showed that 31% of patients had hypertension and up to 15% had congestive heart failure7. The 
results for Pittsburgh, Pa were similar to those of China.  
Obesity has been a public health issue in the United States for decades. Early reports from 
Europe and China have shown a higher prevalence of obesity among patients hospitalized with 
COVID‐19 or who develop adult respiratory distress syndrome. An exciting hypothesis relies on 
fatty tissue possibly being a reservoir for viral replication and shedding. Nevertheless, obesity 
causes an array of underlying health concerns that, when combined with COVID-19, is 
hypothesized to be the cause of increasing severity and disease progression. Obesity was prevalent 
in people under the age of 65 years old. 
Next, chronic kidney disease and renal disease become critical when the kidneys are 
damaged and cannot filter blood efficiently 9. Many individuals with diabetes, hypertension, and 
disease are more susceptible to developing kidney disease, making this a large percentage of 
comorbidities globally. Patients with underlying kidney disease and undergoing dialysis were 
found to have increased mortality when infected with SARS‐CoV‐2 7. Many patients were on 
hemodialysis as noted in their charts. 
Diabetes, Hypertension, cardiovascular disease, obesity, and chronic kidney diseases are 
chronic diseases that increase severity and mortality rates for the at-risk populations. Statistically, 
during the initial outbreak in Wuhan, China, the death rate among individuals with comorbidities 
such as chronic heart disease (10.5%), 7.3%, diabetes (7.3%), Respiratory disease (7%), 
hypertension (6%), and cancer (5%) (AHA,2020) raised concern. We conducted a study that 
                                                 
9 NIH, 2018 
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analyzed comorbidities, risk factors, and personal characteristics to see if there is a pattern in cases 
globally. 
2.4 Comorbidity Compartments 
The Charlson Comorbidity Index is used to assess if a person will live long enough to 
benefit from a specific screening measure or medical intervention. Charlson gave each disease a 
one-year mortality rate scoring number ranging from 1-6 points. In the chart below, the point given 
is in parenthesis under the comorbidity section. With each increased level of the comorbidity 
index, step by step escalations in the accumulative mortality attributable to comorbid diseases 10. 
The patient’s disease history was categorized in the chart below. 
Table 1: Comorbidity Compartments 
 
                                                 
10 Charlson, 1987 
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3.0 Results 
3.1 Statistical Analysis 
A comparison of clinical characteristics between severe and non-severe patients was 
conducted using Microsoft Excel. A two-sided t-test was performed using STATA to find the P-
value and confidence intervals for each variable in Table 1. There were 50 patients comprised of 
31 females and 19 males ranging from the ages of 21-91. Statistically, 30% of patients were severe 
cases. The mean age of the most severe group is 78 years, the majority of which were male. The 
most prevalent risk factor for this group was hypertension (93%), and 60% had congestive heart 
failure. For non-severe cases, the mean age is 66 years, and many suffered from HTN (68%), 
GERD (51%), and diabetes (48%), all of which affected more of the female patients. 
Table 2 Severe Versus Non-Severe Data 
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The majority of patients did not receive any supplemental oxygen. Other severe cases 
included chronic kidney disease (40%) and Respiratory Disease (46%). It is important to note that 
the respiratory disease category included cases related to COVID-19 and non-SARS pneumonia 
cases. We received different outcomes than those of global statistics, as the rate of pulmonary 
disease (6%) and renal disease (8%) for our study were lower than expected. This shows that the 
average general comorbidities changes per region. The lung-related illness was low as COVID-19 
is known to attack the lungs; therefore, conditions such as Asthma were observed, but none of the 
severe patients suffered from it.  
The length of stay was an average of 11 days, although some patients were hospitalized for 
up to 40-55 days. The average BMI is 28%, with obesity in patients averaging 16%. The average 
ICU admission was 30%, all being severe cases. Lastly, a two-sided t-test was performed using 
STATA with a 95% confidence interval. The only P-value that was below the alpha (.05) is 
hypertension (.03). We counted the number of cases, including mild cases, to calibrate the 
epidemic response in Pittsburgh, PA 
 11 
3.2 The Charlson Comorbidity Index 







Patient information that was recorded in October 2020 affected prognosis when rechecked 
in March 2021. Tally marks were used to count the frequency of the disease per patient per age 
group. Seniors over the age of 70 were significantly associated with the disease severity and many 
prognostic endpoints. Comorbidities, including hypertension, diabetes, cardiovascular disease, 
cerebrovascular disease, COPD, GERD, and chronic kidney disease, contributed significantly to 
the disease severity and prognostic endpoints of COVID-19. The Comorbidity Index for 
Scoring 
Total comorbidity component index + Age index = Total comorbidity Score 
Age <50 years: 0 points 
Age 50-59 years: 1 point 
Age 60-69 years: 2 points 
Age 70-79 years: 3 points 
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Hypertension is 5.0 (Age70+) with a frequency of 32 (64%). Cancer has a Comorbidity of 9 (Age 
70+) with a frequency of 9 (18%). 
3.3 Comorbidities by Age   
 
Figure 1: Comorbidities by age 
 
The percent of comorbidities amongst the different age groups were observed from the 
sample of 50 sizes. The results show that the age group (70-79) patients had the highest 
comorbidity counts, which indicates that they are more susceptible to severe disease progression. 
There are no significant outliers in age groups ranging from 20-60 years. The age group 80-89 
years were also susceptible to moderate to severe disease progression as they had the second-
highest rate of comorbidities. The eldest age group did not suffer from strict disease progression 
as their disease frequency was lower than hypothesized. The comorbidity that raised the most 
profound concern is hypertension, and people aged 70-89 experienced high rates of diabetes and 
respiratory distress. 
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3.4 Severity between Gender and Ethnicity 
 
Figure 2: severe and non-severe patients amongst ethnicity and gender 
The severity between gender and ethnicity was graphed to understand severity on personal 
characteristics better. The graph displays the dataset distribution, which shows that males are more 
susceptible to severe cases than females. Among ethnicities, white patients had a slight 
significance in disease severity; it is essential to note that the same statistic applies to non-severe 
cases. The confounding result in this graph is that black people are not more susceptible to severe 
cases as opposed to the CDC’s statistic that they are. Although this is not proven to be incorrect, 
white males were more prominent in disease cases in the Pittsburgh area. 
3.5 Regional Findings 
The figure below distributes the number of cases in the Pittsburgh, PA region. It is 
important to note that not all patient's zip codes were from Allegheny county; thus, those patients 
were not represented in this portion of the paper. Areas with high cases include Shadyside, 
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Brentwood, and downtown Pittsburgh. Shadyside (population 13,915) and downtown Pittsburgh 
(population 5,201) are popular tourist sites within Pittsburgh. Brentwood is a more secluded 
location; therefore, the likely event of transmission occurred amongst residences nearby. 
 
Figure 3: COVID-19 cases in Pittsburgh, PA by zip code 
 
Figure 4: Mild, moderate and severe cases in Pittsburgh, PA by zip code 
In high‐income countries, the burden of comorbidities is greater in the lower socio‐
economic strata and in neighborhoods with poor access to healthcare infrastructure 7. These 
communities may be more inclined to receive the vaccination if they know the rate of disease cases 
in the area. The same notion applies to the older population and knowing which areas to avoid 
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during this pandemic. These areas include places that college students are more prone to associate 
with as they tend to “go out” more than average. It is known that the R0, the average number of 
cases of an infectious disease arising by transmission from a single infected individual in an area 
that has not been exposed, has a higher value when there is a large number of residents because 




Males were more susceptible to severe cases of COVID-19 than females. The most 
concerning statistic is that 76% of all patients had hypertension. Amongst the variables, 46% of 
patients were placed on ventilation treatments and 30% were in the ICU, which could be due to a 
small sample size as we expected more severe cases. Patients under the age of 50 did not 
experience severe disease progression, and the mortality rate for this age group was 0%. The 
average length of stay was 9 days, with the more severe cases experiencing prolonged 
hospitalization of over 20 days. Patients with a history of smoking, vaping, COPD, compromised 
immune systems, or diabetes had prolonged hospitalizations of more than six days. The mortality 
rate was 12% of all patients. The mortality rate was equally divided amongst gender and was 80% 
for White patients compared with 20% for Black patients. Prognosis endpoints were concerning 
for Hypertension, cancer, and GERD.  
Brentwood, Pa, had an unusually high number of cases, though it has a large population of 
28,000 people. Lastly, severe cases were prevalent in popular tourist areas such as Shadyside and 
Ross Township. It is suggested that these areas be avoided for people with underlying health 
concerns to lower the risk of becoming infected. Additionally, low-income areas were not more 
susceptible to severe disease progression, this can be due to each area having their own UPMC 





The measures from the Charlson Comorbidity Index were interpreted with caution because 
it takes time for cases to become severe or for infected persons to die. It may not be possible to 
accurately estimate the denominator of infected people to calculate those ratios. 
4.3 High Risk Population  
Although serious complications resulting from COVID-19 can occur in any individual, 
certain populations are more susceptible to these complications. At-risk populations include older 
adults, those with weakened immune systems, pregnant women, and those with underlying health 
conditions. Our study did not include pregnant women but 99% of our patients have weakened 
immune systems and more than 3 underlying conditions. According to research, over 80% of 
deaths from the disease have been in people age 65 and older 11. In this study, the mortality rates 
were more concerning for people ages 70 years and older.  This shows that the mortality rate for 
this population is extremely high and remains a top priority during this pandemic. 
 The results display that the senior populations are more susceptible to the virus because of 
additional health impairments and personal characteristics when paired with advanced age. Germs 
can spread very quickly between people who live near each other11, implying that the transmission 
rate can be higher amongst seniors residing in a long-term care facility without proper guidelines 
to protect this community. Admissions showed that over 45% of patients were admitted to the 
hospital from long term care facilities. Other patients, above the age 70, had spouses call an 
                                                 
11 Mayo Clinic, 2021 
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ambulance due the patients being unconscious. These patients were often sent to the ICU and 
required ventilation as indicated on their charts.  Some patients 4 of the patients went into Atrial 
Fibrillation that led to a stroke. COVID-19 for these patients were a second infection that 
progressed their underlying conditions.  
Those with compromised immune systems are also at significant risk of severe 
complications resulting from Covid-19. The Mayo Clinic warns that if a person suffers from a 
weakened immune system, those extra precautions are necessary to avoid the virus (Mayo Clinic 
2021) because their body is not equipped to defend itself from the virus, resulting in more severe 
complications. Patients at UPMC Mercy with compromised immune systems required a ventilator 




5.1 Public Health Implementations  
We have sufficient evidence to suggest that the severity experienced by patient increases 
the speed of progression of the virus at a higher rate varying specific risk characteristics during 
hospitalization. Severe cases at UPMC Mercy were analyzed and revealed that some aspects and 
co-infections, not mentioned by the CDC, such as HTN and GERD, increased disease progression 
and prognosis. This study succeeded in its effort to highlight additional personal characteristics, 
risk factors and comorbidities that increases disease severity for public knowledge. This study 
expands the CDC’s findings on disease progression meant to guide people who may feel as if they 
do not fall into the CDC “at-risk” category and expect a mild version of the virus.    
Prevention programs can increase mental health-related issues. When individuals test 
positive for COVID-19, their emotions are erratic. Some have feelings of shame and fear of 
severity levels. This burden falls heavily on the elderly population, who are in constant isolation 
to prevent becoming infected. 
5.2 Future Direction 
More research is needed to pinpoint the severity of disease progression precisely. Research 
is expanding in the United States as most of the research in 2020 was specific to Asia. The data 
from this study shows additional findings that are imperative to update the risk factors that lead to 
severe disease progression for better public understanding. The public may not understand 
different characteristics that pose a threat when combined with infections of COVID-19. An 
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additional future direction could be to investigate the correlation between the genetic aspect of the 
individual patients more susceptible to disease severity and the highlighted comorbidities 
discussed in this paper, as there was not much research on the topic. Lastly, as the COVID-19 
vaccines are now available, the priority groups should be first to receive services, especially the 
elderly population and essential workers. Research should focus on the short-term and long-term 
effects of the vaccine and push for a standard vaccine with results of 100% efficacy to maximize 
benefits and outcomes. Lastly, providing better strategies to target the public in relation to the 
vaccine are vital. During 2020, the efforts were labelled misrepresented as there were many 
confounding factors (Media) that left the public with many conflictions regarding the COVID-19 
vaccine. Nevertheless, since its arrival, the vaccine has lowered the incidence of COVID-19 as we 




Afrin, Lawrence B., Leonard B. Weinstock, and Gerhard J. Molderings. "Covid-19 
hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation 
syndrome." International Journal of Infectious Diseases 100 (2020): 327-332. 
 
Anjorin, A., Abioye, A., Asowata, O., Soipe, A., Kazeem, M., Adesanya, I., Raji, M., Adesanya, 
M., Oke, F., Lawal, F., Kasali, B. and Omotayo, M. (2021), Comorbidities and the COVID‐
19 pandemic dynamics in Africa. Trop Med Int Health, 26: 2-
13. https://doi.org/10.1111/tmi.13504 
 
Charlson M, Peterson J, Szatrowski TP, MacKenzie R, Gold J. Long-term prognosis after peri-
operative cardiac complications. J Clin Epidemiol. 1994 Dec;47(12):1389-400. doi: 
10.1016/0895-4356(94)90083-3. PMID: 7730848. 
 
Charlson, M. E., Pompei, P., Ales, K. L., &amp; MacKenzie, C. R. (1987). A new method of 
classifying prognostic comorbidity in longitudinal studies: Development and validation. 
Journal of Chronic Diseases, 40(5), 373–383. https://doi.org/10.1016/0021-
9681(87)90171-8 
 
Fang, Xiaoyu, et al. "Epidemiological, comorbidity factors with severity and prognosis of COVID-
19: a systematic review and meta-analysis." Aging (Albany NY) 12.13 (2020): 12493. 
 
 22 
Field H. E. (2009). Bats and emerging zoonoses: henipaviruses and SARS. Zoonoses and public 
health, 56(6-7), 278–284. https://doi.org/10.1111/j.1863-2378.2008.01218.x 
 
 
Jin X, Lian J, Hu J, et al Epidemiological, clinical and virological characteristics of 74 cases of 
coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms Gut 2020; 
69: 1002-1009. 
 
       Li Long, Xiansheng Zeng, Xu Zhang, European Respiratory Journal May 2020, 55 (5) 
2000990; DOI: 10.1183/13993003.00990-2020 
 
Moons, K. G., Royston, P., Vergouwe, Y., Grobbee, D. E., & Altman, D. G. (2009). Prognosis and 
prognostic research: what, why, and how?. Bmj, 338. 
 
Morens, D. M., Breman, J. G., Calisher, C. H., Doherty, P. C., Hahn, B. H., Keusch, G. T., Kramer, 
L. D., LeDuc, J. W., Monath, T. P., & Taubenberger, J. K. (2020). The Origin of COVID-
19 and Why It Matters. The American journal of tropical medicine and hygiene, 103(3), 
955–959. https://doi.org/10.4269/ajtmh.20-0849 
 
Ray, Amit. (2020 Apr 8). Life Cycle Analysis of Coronavirus (COVID-19) – The SARS-CoV-2 




Richard A. Stein, Lauren M. Young, From ACE2 to COVID-19: A multiorgan endothelial disease 
International Journal of Infectious Diseases, Volume 100, 2020, Pages 425-430, ISSN 
1201-9712, https://doi.org/10.1016/j.ijid.2020.08.083.  
 
Roach, J. C. (2020). Empirical Model of Spring 2020 Decrease in Daily Confirmed COVID-19 
Cases in King County, Washington. doi:10.1101/2020.05.11.20098798 
 
Wei, Yuan-Yuan, et al. "Risk factors for severe COVID-19: Evidence from 167 hospitalized 
patients in Anhui, China." Journal of Infection 81.1 (2020): e89-e92. 
 
 World Health Organization. (2020). Coronavirus. 
 
 
